{
    "nctId": "NCT01385137",
    "briefTitle": "S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy",
    "officialTitle": "S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III",
    "overallStatus": "COMPLETED",
    "conditions": "Arthralgia, Breast Cancer, Pain",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 262,
    "primaryOutcomeMeasure": "Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary invasive adenocarcinoma of the breast\n\n  * Stage I, II, or IIIA disease\n  * No metastatic disease\n* Must have undergone modified radical mastectomy or breast-sparing surgery and recovered\n* Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+)\n* Currently taking a third-generation aromatase inhibitor (AI) \\[e.g., anastrozole (Arimidex\u00ae), letrozole (Femara\u00ae), or exemestane (Aromasin\u00ae)\\] for \u2265 90 days prior to registration with plans to continue for \u2265 180 days after registration\n* Must have completed the S092 Brief Pain Inventory (BPI)-Short Form within the past 14 days, and must have a worst pain/stiffness of \u2265 5 on the BPI (item #2) that has started or increased with AI therapy\n\nPATIENT CHARACTERISTICS:\n\n* Postmenopausal\n* Zubrod performance status 0-2\n* Willing to submit blood for serum-free estradiol, total estradiol, serum inflammatory markers (IL6, TNF-\u03b1, CRP), DHA and EPA, lipid profile (LDL, HDL, triglycerides), and DNA analysis (CYP19A1)\n* Able to complete study questionnaires in English\n* At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission\n* Patients must not have a known allergy to soy, given that the placebo is suspended in soybean oil\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* At least 3 months since prior omega-3 fatty acid supplements and must agree to refrain from omega-3-fatty acid supplements from sources outside of this study\n* More than 28 days since prior investigational agents\n* No other medical therapy, alternative therapy, or physical therapy for joint pain/stiffness within the past 30 days\n* Patients must not be on anticoagulation medication (i.e., heparin/warfarin) because of increased risk of bleeding within 28 days prior to registration\n* Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to registration\n* Patients must not be on narcotics within 14 days of registration\n* Patients may have received corticosteroid treatment; however, the following criteria apply:\n\n  * Patients must not have received oral or intramuscular corticosteroids within the 28 days prior to registration\n  * Patients must not have received intra-articular steroids to the study, or any other, joint within 28 days prior to registration\n* Patients must not have received topical analgesics (e.g., capsaicin preparations) to the study joint or any other analgesics (e.g., opiates, tramadol; with the exception of nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen) within 14 days prior to registration",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}